Research and Markets: Therapy Trends: Non-small Cell Lung Cancer - KOL Insight Module

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/vr58t3/therapy_trends) has announced the addition of the "Therapy Trends: Non-small Cell Lung Cancer - KOL Insight Module (version 2.0)" report to their offering.

Change is coming to the NSCLC treatment algorithm and it's coming soon. Revolutionary new immunotherapies, more personalised treatment choices and further drug developments are all set to roll out in the near future. What are the potential blockbusters, who will gain approvals first and what are the future challenges?

Drivers of change

Revolutionary immunotherapies. From cancer vaccines to checkpoint inhibitors, several therapies in late-stage development are due to launch very soon. According to KOLs interviewed, the most promising are programmed cell death protein 1 (PD-1) pathway inhibitors. The race is on between Bristol-Myers Squibb's nivolumab, Merck & Co.'s MK-3475 and Roche's RG7446 to become the first to be approved.

Mutation analysis. Personalised targeted therapy has been a paradigm shift towards assessing patients' treatment based on mutation status. Leading the way is Xalkori (crizotinib; Pfizer) with its associated Anaplastic Lymphoma Kinase (ALK)-testing diagnosticyet it faces pending competition from several other therapies in early- to late-stage development.

Key opportunities in EGFR resistance. Since patients all develop resistance to currently marketed EGFR inhibitors, significant opportunities exist in developing a therapy to tackle the T790 mutation responsible for approximately half of acquired resistance cases. While pipeline therapies have not yet proven they have the answer, KOLs believe early phase 1 results from Clovis's CO-1686 position it well.

Unique insider clinical opinion

Comprehensive, concise and offering rare access to the most forward-thinking KOL analysis of NSCLC treatments, development and competition, KOL Insight: Non-small cell lung cancer is an essential tool for keeping abreast of events that will shape the future.

Based on in-depth interviews with 12 experienced and highly-regarded KOLs across North America and Europe, the report provides the latest insights into the current and future treatment landscapes. Chosen for their unique abilities, clinical experience, publications and treatment guideline development as well as presence on the international stage, the KOLs bring incisive, real-world analysis of NSCLC treatment.

Key Topics Covered:

1.Executive summary

2.Research Objectives

3.Research Focus

4.EGFR mutation positive

5.EML4-ALK positive

6.EML4-ALK and EGFR mutation negative

7.Immunotherapy

8.Appendix

For more information visit http://www.researchandmarkets.com/research/vr58t3/therapy_trends

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare and Medical Devices, Pharmaceuticals

Sharing

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare and Medical Devices, Pharmaceuticals